New webinar with Kirsten Müller-Vahl
On Thursday, 28 April, Prof. Dr. Kirsten Müller-Vahl will be a guest in the webinar of the Bedrocan Series. Müller-Vahl is a Professor of Psychiatry in the Department of Psychiatry, Social Psychiatry and Psychotherapy at the Hanover Medical School in Germany. Müller-Vahl has been researching the effect of medicinal cannabis in the treatment of tics and other psychiatric disorders for more than twenty years. In this webinar, Müller-Vahl shares the the most recent CANNA-TICS study results in which the effect of nabiximol was investigated in Gilles de la Tourette patients. She will also speak first-hand about an unpublished study on the use of cannabis among German patients.
As the webinar is a live event, there will be the opportunity to ask questions.
Bio dr. Kirsten Müller-Vahl
Dr. Kirsten R. Müller-Vahl is a Professor of Psychiatry at the Department of Psychiatry, Socialpsychiatry and Psychotherapy at the Hannover Medical School (MHH), Germany. She is a specialist in both neurology and adult psychiatry. In the last 20 years she has investigated more than 1500 patients with Tourette syndrome (TS) (children and adults).
Since 1994 Müller-Vahl has been studying the clinical effects of cannabinoids in the treatment of movement disorders. Subsequently, she performed several studies investigating the effect of delta-9-tetrahydrocannabinol in the treatment of tics and other psychiatric disorders.
Müller-Vahl is a member of the scientific advisory board of the Tourette Society Germany and a board member of the International Working Group for Cannabinoid Medicines (IACM).